Likewise, in 13 patients with heterozygous familial hyperlipidemia and NAFLD, inhibition of PCSK9 improved hepatic steatosis, inflammation and fibrosis [154]. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.